Invst LLC Has $732,000 Position in Stryker Corporation $SYK

Key Points

• Invst LLC has significantly increased its investment in Stryker Corporation by 72.9%, now holding a position worth $732,000 after purchasing an additional 829 shares.
• Insider Viju Menon recently sold 500 shares of Stryker, while Director Ronda E. Stryker sold a much larger quantity of 200,000 shares, indicating movements among company leadership.
• Stryker's quarterly earnings revealed an EPS of $3.13, surpassing estimates, and the company has announced a dividend of $0.84 per share scheduled for payment on October 31st.

Invst LLC grew its stake in Stryker Corporation (NYSE:SYK - Free Report) by 72.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,966 shares of the medical technology company's stock after purchasing an additional 829 shares during the period. Invst LLC's holdings in Stryker were worth $732,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Capital A Wealth Management LLC acquired a new stake in shares of Stryker in the 4th quarter valued at approximately $26,000. Goodman Advisory Group LLC acquired a new stake in Stryker during the 1st quarter worth approximately $32,000. City Holding Co. boosted its position in Stryker by 528.6% during the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock worth $33,000 after buying an additional 74 shares during the period. Ransom Advisory Ltd acquired a new stake in Stryker during the 1st quarter worth approximately $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in Stryker during the 1st quarter worth approximately $40,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Stryker news, insider Viju Menon sold 500 shares of the business's stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares of the company's stock, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company's stock.

Stryker Stock Performance

NYSE:SYK opened at $383.32 on Friday. The company has a fifty day moving average of $388.98 and a 200-day moving average of $379.65. The firm has a market capitalization of $146.55 billion, a P/E ratio of 50.77, a P/E/G ratio of 2.80 and a beta of 0.93. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. Stryker's quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, sell-side analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker's payout ratio is 44.50%.

Analysts Set New Price Targets

Several research firms recently commented on SYK. Wall Street Zen upgraded shares of Stryker from a "hold" rating to a "buy" rating in a research report on Friday, July 18th. Citigroup restated a "buy" rating and set a $455.00 price target (up previously from $443.00) on shares of Stryker in a report on Thursday, May 22nd. Evercore ISI raised their price target on shares of Stryker from $390.00 to $415.00 and gave the stock an "outperform" rating in a report on Tuesday, July 8th. Truist Financial set a $415.00 price target on shares of Stryker and gave the stock a "hold" rating in a report on Monday, August 4th. Finally, Needham & Company LLC raised their price target on shares of Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Fourteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Stryker has a consensus rating of "Moderate Buy" and a consensus target price of $431.42.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.